FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386024370> ?p ?o ?g. }

• W4386024370 endingPage "e0950015" @default.
• W4386024370 startingPage "e0950015" @default.
• W4386024370 abstract "Background: Acute myeloid leukemia (AML) is the most common type of acute leukemia in adult pts, including pregnant. AML accounts for two-thirds of all cases of acute leukemia diagnosed during pregnancy. Formulated more than 25 years ago, the postulate about the neсessity for “saving two lives” formed the basis of a systematic approach to the treatment of acute leukemia in pregnant pts with AML, and allowed to develop appropriate clinical protocols. Aims: To assess prognostic impact of allo-HSCT conducted in CR1 in pregnant pts with AML. Methods: In total 45 pregnant pts with AML were included in the multicenter research. All pts were divided into two groups: the 1st group included 20 pts (a set of pts from 1997 to 2014), who were scheduled to undergo allo-HSCT in the first complete remission (CR1) only in the presence of an unfavorable karyotype, the 2nd group - 25 pts (a set of pts from 2015 to 2021), who were scheduled to undergo allo-HSCT in CR1, regardless of the karyotype. The control group consisted of non-pregnant fertile women who received treatment at the National Medical Research Center for Hematology from 2015 to 2021 (n=55). Landmark analysis was performed in group of pregnant pts with CR1 of AML (n = 35) and in the control group (n = 49). The landmark point for pts who underwent allo-HSCT was the date of allo-HSCT, and for the rest – the date of CR plus the median time to allo-HSCT, which in pregnant pts was 190 days (6.3 months) (17-270 days). Results: CR was achieved in 78% of pregnant pts in total (n=35): in 75% of pts from 1st group (n=15) and in 80% of pts from 2nd group (n=20). In the control group the frequency of CR was 89% (n=49). The percent of pts who underwent allo-HSCT was 2.5 times greater in group 2 than in group 1: 68% and 30%, respectively (p = 0.029). In the control group, this indicator was 60%. It was found that performing allo-HSCT in CR1 significantly improved RFS in pregnant women with AML compared to those who did not underwent allo-HSCT (Fig. 1A). In order to assess the combined prognostic impact of various factors on RFS for groups of pts treated under a single program (group 2 and comparison group), a multifactorial analysis of RFS with step-by-step selection of factors was carried out. The following factors were included in the model as candidates: pregnancy, ELN risk group, time when CR was achieved (after the 1st course of induction, or after the 2nd course of induction) and the performance of allo-HSCT in CR1 as a time-dependent factor (the factor does not act until the time of transplantation). The only factor selected for the final model was the performance of allo–HSCT (p = 0.0108). Thus, this factor neutralized impact of other factors, including pregnancy. Figure 1B shows the OS estimated for three subgroups of pts: pregnant women with AML who were treated before 2015 (1st group), pregnant women with AML who were treated after 2015 (2nd Group), and non-pregnant fertile women with AML (control group). The median follow-up time was 17.5 months. Although there were no statistically significant differences between the subgroups, the OS in 2nd group was higher than in 1st group. This difference is observed due to the performance of allo-HSCT in CR1. Summary/Conclusion: It was found that pregnancy is an unfavorable prognostic factor in pts with AML. However, the implementation of allo-HSCT in CR1 allows to neutralize the negative influence of this factor. Thus, women who are diagnosed with AML during pregnancy are candidates for performing allo-HSCT in CR1.Keywords: Chemotherapy, Pregnancy, Acute myeloid leukemia" @default.
• W4386024370 created "2023-08-22" @default.
• W4386024370 creator A5007492525 @default.
• W4386024370 creator A5008001740 @default.
• W4386024370 creator A5008276842 @default.
• W4386024370 creator A5009035077 @default.
• W4386024370 creator A5009453463 @default.
• W4386024370 creator A5015088338 @default.
• W4386024370 creator A5019917735 @default.
• W4386024370 creator A5038042903 @default.
• W4386024370 creator A5046495435 @default.
• W4386024370 creator A5046804186 @default.
• W4386024370 creator A5047533978 @default.
• W4386024370 creator A5057317122 @default.
• W4386024370 creator A5066470513 @default.
• W4386024370 creator A5074330954 @default.
• W4386024370 creator A5079102189 @default.
• W4386024370 date "2023-08-01" @default.
• W4386024370 modified "2023-09-26" @default.
• W4386024370 title "P569: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PREGNANT WOMEN WITH ACUTE MYELOID LEUKEMIA" @default.
• W4386024370 doi "https://doi.org/10.1097/01.hs9.0000969180.09500.15" @default.
• W4386024370 hasPublicationYear "2023" @default.
• W4386024370 type Work @default.
• W4386024370 citedByCount "0" @default.
• W4386024370 crossrefType "journal-article" @default.
• W4386024370 hasAuthorship W4386024370A5007492525 @default.
• W4386024370 hasAuthorship W4386024370A5008001740 @default.
• W4386024370 hasAuthorship W4386024370A5008276842 @default.
• W4386024370 hasAuthorship W4386024370A5009035077 @default.
• W4386024370 hasAuthorship W4386024370A5009453463 @default.
• W4386024370 hasAuthorship W4386024370A5015088338 @default.
• W4386024370 hasAuthorship W4386024370A5019917735 @default.
• W4386024370 hasAuthorship W4386024370A5038042903 @default.
• W4386024370 hasAuthorship W4386024370A5046495435 @default.
• W4386024370 hasAuthorship W4386024370A5046804186 @default.
• W4386024370 hasAuthorship W4386024370A5047533978 @default.
• W4386024370 hasAuthorship W4386024370A5057317122 @default.
• W4386024370 hasAuthorship W4386024370A5066470513 @default.
• W4386024370 hasAuthorship W4386024370A5074330954 @default.
• W4386024370 hasAuthorship W4386024370A5079102189 @default.
• W4386024370 hasBestOaLocation W43860243701 @default.
• W4386024370 hasConcept C126322002 @default.
• W4386024370 hasConcept C143998085 @default.
• W4386024370 hasConcept C187212893 @default.
• W4386024370 hasConcept C194409129 @default.
• W4386024370 hasConcept C2776863199 @default.
• W4386024370 hasConcept C2777408962 @default.
• W4386024370 hasConcept C2778461978 @default.
• W4386024370 hasConcept C2778729363 @default.
• W4386024370 hasConcept C2779234561 @default.
• W4386024370 hasConcept C2911091166 @default.
• W4386024370 hasConcept C54355233 @default.
• W4386024370 hasConcept C71924100 @default.
• W4386024370 hasConcept C86803240 @default.
• W4386024370 hasConceptScore W4386024370C126322002 @default.
• W4386024370 hasConceptScore W4386024370C143998085 @default.
• W4386024370 hasConceptScore W4386024370C187212893 @default.
• W4386024370 hasConceptScore W4386024370C194409129 @default.
• W4386024370 hasConceptScore W4386024370C2776863199 @default.
• W4386024370 hasConceptScore W4386024370C2777408962 @default.
• W4386024370 hasConceptScore W4386024370C2778461978 @default.
• W4386024370 hasConceptScore W4386024370C2778729363 @default.
• W4386024370 hasConceptScore W4386024370C2779234561 @default.
• W4386024370 hasConceptScore W4386024370C2911091166 @default.
• W4386024370 hasConceptScore W4386024370C54355233 @default.
• W4386024370 hasConceptScore W4386024370C71924100 @default.
• W4386024370 hasConceptScore W4386024370C86803240 @default.
• W4386024370 hasIssue "S3" @default.
• W4386024370 hasLocation W43860243701 @default.
• W4386024370 hasOpenAccess W4386024370 @default.
• W4386024370 hasPrimaryLocation W43860243701 @default.
• W4386024370 hasRelatedWork W2161603182 @default.
• W4386024370 hasRelatedWork W2345640867 @default.
• W4386024370 hasRelatedWork W2350274480 @default.
• W4386024370 hasRelatedWork W2366793411 @default.
• W4386024370 hasRelatedWork W2367183733 @default.
• W4386024370 hasRelatedWork W2388787066 @default.
• W4386024370 hasRelatedWork W2393383561 @default.
• W4386024370 hasRelatedWork W2394313917 @default.
• W4386024370 hasRelatedWork W2417324750 @default.
• W4386024370 hasRelatedWork W2936131736 @default.
• W4386024370 hasVolume "7" @default.
• W4386024370 isParatext "false" @default.
• W4386024370 isRetracted "false" @default.
• W4386024370 workType "article" @default.